The University of Texas MD Anderson Cancer Center Renovate Alkek Hospital, Main Bldg., Floor 12 - 150606/ME Introduction to MD Anderson MD Anderson is known throughout the world for high-quality cancer care, research, academic programs and prevention services. Since its establishment in 1941, MD Anderson has made major contributions to improve the outlook for cancer patients everywhere. MD Anderson was one of the first three federally designated comprehensive cancer centers by the National Cancer Act of 1971. A survey of health professionals has routinely ranked MD Anderson as one of the two premier cancer centers in the nation for the past eight years. Over 55,000 persons annually seek care at MD Anderson. The team approach to cancer care, pioneered at MD Anderson, has been strengthened by consolidating specialty clinics into multi-disciplinary care centers that allow patients to receive more ambulatory care and treatment in a single location. MD Anderson offers one of the largest bone marrow and stem cell transplantation programs, as well as clinical trials to improve existing therapies. Teams of clinical specialists collaborate with scientists on problems of common interest and test theories that shorten the application of better treatment methods. Translational research studies are responsible for the promising field of chemoprevention, which uses synthetic vitamins to reverse pre-malignant lesions and halt the recurrence of some cancers, and for innovative gene therapy strategies being evaluated for several forms ofcancer. With faculty and staff working in more than 30 buildings in the greater Houston area and in central Texas, MD Anderson is the largest freestanding cancer center in the world. The physical plant covers more than 11 million square feet, featuring the latest equipment and facilities to support growing needs in outpatient and inpatient care, research, prevention and education. It includes inpatient hospital facilities with 571 beds. Construction projects include the addition of 12 floors that can accommodate more than 300 new inpatient beds in Alkek Hospital on the North Campus; two new research buildings on the South Campus that will house the Center for Advanced Biomedical Imaging Research and Center for Targeted Therapy as part of the McCombs Institute; and MD Anderson's first facility on its Mid Campus, a 25-story building to support current office space and future growth needs. In addition to its main campus in the Texas Medical Center and two research campuses in Bastrop County, Texas, MD Anderson has developed a number of local, national and international affiliations RFx Overview PROJECT DESCRIPTION The Project is anticipated involve the heavy renovation of approximately 43,000 gross square feet on Floor 12 of the Alkek Hospital, which is part of the Owner’s main Building complex. The renovation is expected to include, but not necessarily be limited to: • Enclosing medicine preparation areas; • Renovating infrastructure systems to facilitate the use of technologies consistent with those being used for patient care on Alkek Expansion floors and/or Epic (including infrastructure work for the addition of physiological monitoring capabilities, as deemed necessary); • Evaluating, and designing modifications as required, to the air handling system to ensure adequate air distribution and circulation; • Upgrading all finishes; • Installing bathrooms in those patient rooms that have none; • Evaluating the floor, and designing modifications as required, to ensure it is up to current codes and guidelines; and • Create a phasing plan to coincide with implementing changes to utility systems that are shared with occupied areas. PRE-SUBMITTAL CONFERENCE: A non-mandatory pre-submittal conference will be held at the time and location described below. Although not required, attendance is encouraged to allow interested parties an opportunity to hear Owner discuss the Project and the selection process. JULY 2, 2018 @ 10:00 AM LOCAL TIME The University of Texas MD Anderson Cancer Center FANNIN HOLCOMBE BUILDING 6900 FANNIN CONFERENCE ROOM 3.1021 HOUSTON, TEXAS, 77030 A guided tour of the project site will not be included as a part of the conference agenda. Questions related to this RFP must be sent via the information request form. All questions must be received no later than July 6, 2018 4:00 PM. Questions received after this time will not be accepted. Questions will not be answered via telephone. All answers to any questions or inquiries will be posted on the webpage for all Suppliers to access. It is the intent of MD Anderson to respond to all questions and concerns; however, MD Anderson shall reserve the right to decline to respond to any question or concern. It is important to note that the supplier or suppliers selected to develop MD Anderson's RFP are not automatically qualified to engage with the Institution for purposes of implementing the recommended strategy or solutions. The engagement of contracted services for implementation can, at MD Anderson's discretion, be solicited via a second and separate Request for Proposal. Standard Riders and Agreements AA RFQ.pdf Addendum 1 Sign In Sheets, HUB Sheet, Drawings.pdf Addendum 2 RFI Questions and Answers.pdf Attachment A Draft Agreement and Exhibits.pdf Attachment B HUB Policy Rider 104B.pdf Attachment C RFI Form.pdf Attachment D Pre-Design Report.pdf Attachment E Gift Policy.pdf.pdf ***Interested suppliers should also note that Subcontracting Opportunities are probable in connection with this solicitation. Please review the HUB Subcontracting Tip Sheet ***RFx refers to RFP, RFQ, RFI, ITB, etc. Return to Supply Chain Management List of Current Bids.

Bid Protests Not Available